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The Left Ventricle in Dogs with Myxomatous Mitral Valve Disease. 
Remodeling and Overall Performance. 
Abstract 
The concept of left ventricular (LV) remodeling in dogs with myxomatous mitral 
valve disease (MMVD) includes changes in the LV occurring in response to mitral 
regurgitation (MR). The general aim of this thesis was to study LV remodeling and 
function in dogs with different severities of naturally acquired MMVD using 1) 
digital signal analysis technique for murmur and heart sound assessment, 2) 
biomarker analyses of circulating cardiac troponin I (cTnI), C-reactive protein 
(CRP), and matrix metalloproteinases (MMPs), and 3) real-time three-dimensional 
(RT3D) echocardiography for assessment of changes in LV shape and volume.  
Digital linear and nonlinear analyses (using seven different sound variables) of 
cardiac sounds  showed that  more severe  MR produced  a murmur of “harsher” 
quality, longer duration, and with more complexity in the signal. The energy of the 
first heart sound  was not associated with MR severity (assessed by 
echocardiography), whereas the energy of the second heart sound decreased with 
increasing MR severity. Biomarker assessments showed circulating  (cTnI) 
concentration to increase with increasing disease severity, whereas circulating C-
reactive protein (CRP) concentration was not associated with disease severity. 
Neither MMP-2 nor -9 were associated with the MMVD severity groups (which 
was mainly based on volume overload status), however, MMP-9 activity decreased 
with worsening systolic  function. The RT3D echocardiographic examinations 
showed prominent LV volume expansions only in dogs with more severe MMVD. 
The mid LV segment contributed the most to the global volume increase. The LV 
shape changed from elliptical to more globular in response to increasing volume 
overload, with the basal and apical segments contributing the most to the increase in 
sphericity.  
In conclusion, the findings in the present thesis provide data that  might 
contribute to the understanding of the complex pathophysiology of MMVD; 
thereby potentially impacting both clinical management and prediction of outcome 
for affected dogs in the future. 
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1  Introduction 
 
1.1  General background 
The concept of ventricular remodeling, which was coined in the 1980s 
(Pfeffer  et al., 1985), is applied when describing ventricular changes 
occurring in response to hemodynamic changes of various etiologies (Opie 
et al., 2006). The ventricular remodeling processes include left ventricular 
(LV) dilation, changes in LV shape, and LV muscle mass hypertrophy 
(Cohn, 1995); which all might adversely affect cardiac performance.  
 In 1817, Delabere Blaine described abnormal heart beats to “afford a 
decided characteristic of the complaint”, detectable as a thrill when placing 
the hand on the side of the chest of a dog; thus indicating the presence of a 
cardiac disease  (Blaine, 1817).  Pathological changes of the mitral valve 
apparatus in dogs, possibly caused by valve degeneration, was described in 
the literature as early as 1935 (Münich, 1935). The knowledge in veterinary 
cardiology has improved tremendously since then, and assessment of cardiac 
diseases can nowadays be performed using various diagnostic techniques. As 
a result, myxomatous mitral valve disease (MMVD) has been proven the 
most prevalent cardiac disease in dogs (Buchanan, 1977; Whitney, 1974; 
Das & Tashjihan, 1965;  Detweiler & Patterson, 1965),  and hence, the 
disease most commonly causing LV remodeling in dogs. The highest disease 
prevalence in dogs is seen in small to medium-sized breeds, such as Cavalier 
King Charles Spaniel (CKCS), Dachshunds, miniature Poodles, and 
Yorkshire Terriers (Egenvall et al., 2006; Olsen et al., 1999; Haggstrom et 
al., 1992; Darke, 1987; Buchanan, 1977). The prevalence increases with age 
and is, at a given age, higher in males (Olsen et al., 1999; Häggström et al., 
1992; Buchanan, 1977; Whitney, 1974; Das & Tashjihan, 1965; Detweiler  
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& Patterson, 1965). Affected dogs have no signs of valve abnormalities at 
birth, but develop MMVD later in life. The etiology of MMVD is currently 
not known, but the current leading scientific hypothesis is that a genetically 
determined dystrophic process, rather than succession of repeated trauma of 
the valve leaflets, initiates the valve degeneration  (Olsen  et al., 1999; 
Swenson et al., 1996). This hypothesis is strengthened by the knowledge 
that some breeds, such as the CKCS and Dachshund, are predisposed to an 
early onset of MMVD (Lewis et al., 2011; Olsen et al., 1999; Swenson et al., 
1996; Häggström et al., 1992). The disease, which has been described to 
strongly resemble primary mitral valve prolapse (MVP) syndrome in people 
(Pedersen & Häggström, 2000), is characterized by progressive degeneration 
of the mitral valve (Kogure, 1980; Buchanan, 1977; Whitney, 1974). The 
valve degeneration leads to mitral valve leakage, referred to as mitral 
regurgitation (MR),  and subsequently chronic volume overload with 
dilation of the left atrium (LA) and the LV. Progression of the disease varies 
between individuals, but affected dogs can usually compensate the MR for 
years. Eventually the heart might become incapable of meeting the increased 
work load imposed upon it and congestive heart failure (CHF) develops. An 
increased cardiac mortality before the age of 10 years has been shown in dog 
breeds affected by an early onset of MMVD (Egenvall et al., 2006).  
The mechanisms involved in the remodeling process of MMVD remain 
poorly characterized and understood; partly owing to the slow progression 
from early degenerative changes to development of CHF;  which 
complicates studies of disease progression. Cardiac remodeling processes in 
experimental settings as well as in acute vascular diseases in other species 
have been more extensively documented (Lang et al., 2006a; Stewart et al., 
2003; Dell'Italia et al., 1995). However, these cardiovascular events differ 
fundamentally from naturally acquired chronic cardiac disease in origin and 
progression, which emphasizes the importance of investigating the LV 
remodeling process also in dogs with naturally acquired MMVD. Studying 
LV remodeling in dogs with different severities of MMVD using recently 
developed diagnostic techniques, such as sound analysis techniques, 
magnetic resonance imaging, real-time three-dimensional  (RT3D) 
echocardiography, and high sensitivity biomarker assays, as well as more 
established techniques, might reveal new concepts of pathophysiological 
changes occurring during MMVD progression. Increased knowledge of 
these complex pathophysiological processes might, hopefully, be of value for 
improved clinical management of the individual dog affected by the disease.  
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2  The mitral valve apparatus 
2.1  Normal anatomy and function 
The mitral valve apparatus includes six anatomical elements; the posterior 
LA wall, the mitral orifice, the leaflets (the posterior and anterior), the 
chordae tendineae, the papillary muscles, and the LV wall; which all work in 
fine concert to maintain competence (Perloff & Roberts, 1972).  
 
Figure 1.  Normal anatomy of the canine heart.  
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In addition to serving as a hinge for the leaflets, the mitral orifice reduces 
the area required for the leaflets to bridge during ventricular systole (the 
ventricular contraction period) by decreasing its circumferential size (Ahmed 
et al., 2009; Brolin, 1967; Davis & Kinmonth, 1963). A larger surface area of 
the leaflets compared to the annulus area, as described in people, works as a 
reserve for leaflet coaptation; hence preventing backflow of blood (Ahmed 
et al., 2009; Perloff & Roberts, 1972). Each leaflet is supported by fibrous 
strands (chordae tendineae), which insert on papillary muscles arising from 
the apical and middle sections of the LV wall. When the LA pressure 
exceeds the LV pressure, the mitral valve opens and the LA empties into the 
LV. The mitral valve closes completely during LV systole to prevent 
retrograde flow. The mechanisms involved in closure of the mitral valve are 
not fully understood, and different events are probably involved in this 
process (Little, 1979). The LV filling pressure stretches the LV wall to its 
greatest geometric dimension (preload)  during ventricular diastole. The 
increased intraventricular pressure during early systole forces the mitral valve 
to close  by synergistic contraction of the LV walls; resulting in an 
appropriate application of vertical force to the chordae tendineae and hence, 
prevention of leaflet-eversion into the LA (Perloff & Roberts, 1972). Likely, 
significant reduction in the mitral orifice area contributes to closure of the 
mitral valve (Tsakiris et al., 1971; Chiechi et al., 1956). The mitral valve 
orifice is finally sealed when the free edges of the mitral valve leaflets firmly 
coapt.  
 
2.2  Myxomatous mitral valve degeneration 
Myxomatous mitral valve disease  in dogs is characterized by progressive 
myxomatous  degeneration  of the mitral valve apparatus (Kogure, 1980; 
Buchanan, 1977; Whitney, 1974). Although the myxomatous degeneration 
most commonly affects the mitral valve; any of the four intracardiac valves 
can be affected. However, the pulmonary and aortic valves (the semilunar 
valves) rarely develop such degenerative changes (Buchanan, 1977). 
Histopathological findings include myxomatous degeneration (which refers 
to a characteristic pathological weakening  and disturbance in the 
organization of the connective tissue) in which the spongiosa component is 
unusually prominent, and the collagen fibers are disorganized in the fibrosa 
layer  (Hadian  et al., 2010;  Hadian  et al., 2007;  Black  et al., 2005). 
Proteolytic enzymes, such as the matrix metalloproteinases (MMPs), might 
be involved in the degenerative processes leading to atypical organization of  
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connective tissue components  (Aupperle  et al., 2009b;  Aupperle  et al., 
2009c; Dreger et al., 2002). An increased amount of mucopolysaccarides, 
and glycosaminoglycans are commonly seen within affected valves (Han et 
al., 2010;  Hadian  et al., 2007;  Kogure, 1980).
  Characteristic findings of 
endothelial cells covering  the valve surface  include  pleomorphism and 
damage to the  cell-lining. The endothelial damage, which is most 
commonly evident near the edges of the valve leaflets, can cause regional 
loss of endothelial cells; hence exposing underlying basement membranes or  
subendothelial matrix (Corcoran et al., 2004). Endothelial damage induces 
the release of vasoactive peptides, such as endothelin-1, which potentially is 
involved in transforming subendothelial valvular interstial cells (VICs) from 
a predominantly fibroblast phenotype into more active myofibroblast and 
smooth muscle cell phenotypes (Black et al., 2005; Corcoran et al., 2004; 
Mow & Pedersen, 1999). The transformation of VICs has also been 
suggested to be initiated by serotonin (5HT) (Oyama & Levy, 2010; Arndt 
et al., 2009).   
The mitral valve leaflets, which normally are thin, translucent and soft, 
become thickened and elongated with disease progression (Han et al., 2010; 
Corcoran et al., 2004; Kogure, 1980). The chordae tendineae also become 
affected by the myxomatous degeneration (Corcoran et al., 2004; Beardow 
& Buchanan, 1993); resulting in elongation (Kogure, 1980), which together 
with distortion of the valve architecture, contributes to systolic atrial 
displacement of the mitral valve leaflets (i.e. mitral valve prolapse) (Pedersen 
et al., 1996). The thickened and elongated chordae tendineae might rupture, 
which potentially worsens MR by causing leaflets to partially or completely 
prolapse (valve flail) into the LA (Beardow & Buchanan, 1993).  
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Figure 2. Post-mortem specimen of a dog with end-stage MMVD. The mitral valve leaflets 
appear irregularly thickened and contracted. There is also evidence of chordal engagement. 
Chordal rupture, particularly of lesser-order chordae, is a common finding, but not clearly 
apparent in this image. The left atrium and left ventricle are dilated and there is evidence of 
jet lesions on the atrial wall (which occur when the regurgitant jet of blood from the left 
ventricle strikes the atrial wall) 
2.3  Mitral regurgitation 
The degenerative changes of the mitral valve and the corresponding chordae 
tendineae lead to abnormal coaptation of the mitral valve leaflets during 
ventricular systole; why a percentage of the LV stroke volume is ejected 
backwards into the LA. The retrograde ejection of LV stroke volume starts 
already in early systole; leading to a short isovolumetric contraction period 
(defined as the interval between closing of the atrioventricular valves and 
opening of the semilunar valves) (Lord, 1974; Eckberg et al., 1973). The 
extra pathway (into the LA) for stroke volume ejection reduces the LV 
afterload (the resistance to LV emptying). Most commonly, dogs with 
MMVD have a laterally directed MR jet, presumably because the anterior 
leaflet is longer and has a greater mobility than the posterior leaflet (as 
described in dogs and people) (Ahmed et al., 2009; Borgarelli, 2004), and 
hence, is more likely to prolapse than the posterior leaflet. However, the 
spatial orientation of the jet is not constant, particularly not in mild cases of 
MR, probably due to changes in the shape and orientation of the mitral 
orifice area during LV contraction (Tsakiris et al., 1971).   
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Figure  3.  Left apical four-chamber views of the heart in a dog with mitral regurgitation 
caused by MMVD. A schematic drawing of the anatomy of the heart is shown in the same 
orientation as the echocardiograms (A). The echocardiograms show the identical image frame 
with the color mode off (B) and on (C). There is systolic displacement of the mitral valve 
leaflets (B) and valve leakage (C) as indicated by the turbulent flow (mosaic appearance on 
the  color echocardiogram) in the left atrium. On the left ventricular side, blood is 
accelerating towards the regurgitant orifice, after which the flow becomes turbulent and is 
primarily directed laterally in the left atrium. The driving force for the jet is the pressure 
gradient between the left ventricle and atrium, which typically leads to flow velocities 
between 5.5 to 6 m/sec until late stages of the disease. Because the cross-sectional area 
changes from being comparably small at the regurgitant orifice to large on the atrial side, the 
flow becomes turbulent. In the left atrium, the kinetic energy of the jet is transformed into 
heat and vibrations, which are audible as a heart murmur on the thoracic wall.  LA-left 
atrium, LV-left ventricle, RA-right atrium, RV–right ventricle. 
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The MR volume has been described to depend on the mitral valve 
orifice area, and the systolic pressure gradient between the LA and the LV 
(Mihalatos et al., 2007; Pierpont & Talley, 1982), of which the latter is 
influenced by the intra-atrial pressure, the LV function, as well as the 
systemic arterial blood pressure. The myxomatous degeneration of the mitral 
valve apparatus causes an abnormal leaflet-apposition, and hence primary 
MR,  whereas left sided cardiac dilation exaggerates the abnormal valve 
apposition, leading to a secondary MR (Ahmed  et al., 2009;  Buchanan, 
1977).  Consequently, regurgitation begets regurgitation.  Several 
mechanisms have been described involved in production of secondary MR: 
The LV dilation prevents the orifice from fully decreasing its circumferential 
size during ventricular systole (Buchanan, 1977; Brolin, 1967). In addition, 
the altered LV shape causes the laterally displaced papillary muscles to exert 
a more lateral, rather than vertical, force of exertion on the leaflets; hence 
further separating the mitral leaflets in systole (Hung et al., 2004; Lapu-Bula 
et al., 2002; Otsuji et al., 1997; Kono et al., 1992; Buchanan, 1977). Left 
atrial dilation might also aggravate the preexisting MR due to further leaflet 
displacement  (Levy & Edwards, 1962).  Expansion of the LA  buffers the 
increasing MR volume, thereby allowing the intra-atrial pressure to remain 
comparably low, and blood can easily be ejected into the LA during 
ventricular systole, even in dogs with severe MMVD. More than 75% of the 
total LV stroke volume has been reported to be ejected into the LA during 
systole in dogs with severe MMVD (Kittleson & Brown, 2003).  The 
severity of left sided cardiac dilation is linked to MR severity, suggesting 
that MR volume is the major determinant factor for the degree of left sided 
cardiac dilation (Eriksson et al., 2010; Kittleson & Brown, 2003).  
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3  The left ventricle 
3.1  Myocardial histology 
The LV myocardium in dogs has been shown to be composed of muscle 
layers  with a characteristic three-dimensional  (3D)  organization, running 
radially across the LV wall from subendocardium to subepicardium (LeGrice 
et al., 1995). Most of the myocardium is occupied by cardiac myocytes. 
Each  myocyte is composed of bundles of myofibrils, which comprise 
longitudinally arranged  microanatomical units termed sarcomeres. The 
sarcomeres, which represent the basic contractile units of the myocyte, are 
composed of thick and thin filaments; myosin and actin, respectively. 
Chemical and physical interactions between actin and myosin cause 
myocyte contraction; effected by sliding filaments along one another (Katz, 
2001; Walker & Spinale, 1999). 
 
 
Figure  4.  Histologic section  of the myocardium showing myocytes, extracellular matrix 
(ECM) and a blood vessel. Haemotoxylin & eosin staining. (Courtesy of Fredrik Södersten)  
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Structural integrity and overall geometry of the heart is maintained by 
the extracellular matrix (ECM), which tethers individual myocytes together 
in proper alignment within the myocardium, hence working as a cardiac 
framework (Spinale, 2002; Weber et al., 1988; Robinson et al., 1983). This 
structural organization provides tensile strength to the myocardium; 
enabling transduction of contractile force generated by the myocytes in 
systole (Pelouch et al., 1993; Weber, 1989; Robinson et al., 1986). The 
cardiac fibroblast is the most abundant cell type within the ECM and most 
ECM components are produced exclusively by these cells (Pelouch et al., 
1993; Robinson et al., 1983). The fibroblasts can also secrete enzymes that 
regulate ECM turnover; such as the MMPs, their tissue inhibitors (TIMPs), 
as well as other proteolytic enzymes (Hutchinson et al., 2010). Collagen 
subtypes and fibronectin compose the majority of the ECM proteins 
responsible for maintaining structural integrity of the myocardium (Pelouch 
et al., 1993). 
3.2  Left ventricular changes in response to mitral regurgitation 
Mitral regurgitation results in an increased total LV stroke volume as blood 
is ejected both forward into the aorta and retrograde into the LA. In order 
to accommodate the increase in preload, the  LV undergoes various 
compensatory responses. 
3.2.1  Changes in the myocardium 
Changes in the composition and structure of both the ECM and the 
myocytes have been reported in dogs with MR, but the underlying cellular 
and molecular bases for these changes remain poorly understood. The ECM 
is a highly adaptive structure, which has been shown to play a fundamental 
role in myocardial adaptation to pathological stress; thereby facilitating 
remodeling (Weber et al., 1992). The remodeling process of the ECM has 
been suggested to occur as a mechanically mediated response to stretch 
caused by volume overload and/or due to selective induction of proteolytic 
enzymes, such as the MMPs (Woessner, 1991). Normal collagen chains are 
fractured and replaced by poorly cross-linked collagen, resulting in loss of 
normal structural support and myocyte slippage  (Zheng  et al., 2009; 
Dell'italia et al., 1997; Kato et al., 1995). The myocytes are exposed to an 
abnormal stress-and-strain pattern  during the cardiac cycle, particularily 
during diastole owing to increased filling pressure (preload) (Spinale, 2002; 
Pelouch  et al., 1993;  Grossman  et al., 1975).  This triggers an unnatural 
growth response with myocyte hypertrophy and replication of sarcomeres in  
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series;  so-called eccentric hypertrophy (Grossman  et al., 1975), thereby 
increasing myocyte length (Katz, 1990).  Ventricular muscle mass is 
determined by the net difference between synthesis and degradation rate, 
and development of myocardial hypertrophy due to volume overload has 
been suggested to be caused by a decrease in degradation, rather than an 
increase in synthesis of contractile proteins (Carabello, 2002). Myocardial 
hypertrophy has also been suggested stiumulated by an increased 
neurohormonal activation, such as by increased formation of angiotensin II 
(AII) (Morgan & Baker, 1991; Schelling et al., 1991). In dogs with naturally 
occurring MR caused by MMVD, circulating  levels of AII appear 
comparably unchanged during progression from mild MMVD to overt 
CHF (Haggstrom et al., 1997). However, the canine myocardium is most 
likely capable of forming AII locally in the heart in response to 
hemodynamic wall stress: Angiotensin converting enzyme (ACE), chymase 
and cathepsin D have all been reported capable of promoting tissue AII 
formation in the volume over-loaded canine heart (Stewart  et al., 2003; 
Barlucchi et al., 2001; Dell'Italia et al., 1995).   
The  structural  changes  in the cardiac ECM and myocytes allow for 
chronic dilatation without overstretching of the myocytes, thereby 
minimizing  the effects on the myocardium from the increased volume 
overload  (Komamura  et al., 1993;  Anversa  et al., 1986).  The  resulting 
eccentric hypertrophy is characterized by chamber enlargement, but with 
maintained relative wall thickness; sufficient to normalize pressure in the 
volume overloaded LV and maintain an adequate forward stroke volume 
(Carabello, 2002). However, the LV mass-to volume ratio has been shown 
to decrease with progression of MR in dogs (both naturally acquired and 
experimentally induced MR) and in people  (Borgarelli  et al., 2007; 
Carabello, 2000;  Dell'Italia  et al., 1995;  Katz, 1995;  Urabe  et al., 1992; 
Grossman  et al., 1975),  indicating insufficient degree  of hypertrophy to 
accommodate severe volume overload.  
The compensatory mechanism, such as LV hypertrophy, dilation, and 
enhanced activity of the neurohormonal system, are all initially considered 
beneficial in order to provide the hemodynamic support needed to maintain 
sufficient cardiac output despite MR. However, with progression of disease, 
these mechanisms themselves become factors leading to deterioration of the 
failing heart; such as by myocyte injury and accumulation of collagen fibers 
(i.e. myocardial fibrosis) (Opie, 2002; Cohn et al., 2000; Sabbah et al., 1995; 
Grossman et al., 1975).   
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Figure 5. Histologic section of the myocardium in a dog. The center of the image shows an 
intramyocardial artery with arteriosclerotic changes of the vessel wall. The vessel is 
surrounded by demarcated myocardial fibrosis. Masson trichrome staining. (Courtesy of 
Lennart Jönsson).  
3.2.2  Changes in left ventricular size, shape, and function.  
Changes in the myocardium induced by chronic volume overload in 
MMVD dogs will, in turn, impact size, shape and mechanical function of 
the heart. The LV has been suggested to obtain a more globular rather than 
elliptical shape with increasing volume overload, as seen in human and 
canine cardiac diseases of varying etiologies  (Di Donato  et al., 2006; 
Monaghan, 2006;  Lord, 1974).  However, sparse information is available 
regarding the transition into a more globular shape in dogs with naturally 
occurring MMVD. Interactions between myocardial structure and function 
exist,  and the systolic function has been shown to decline in dogs with 
naturally acquired MMVD and in dogs with experimentally induced MR 
(Borgarelli  et al., 2007;  Urabe  et al., 1992).  Mechanisms underlying this 
deterioration are  poorly understood, but various hypotheses have been 
suggested.  Left ventricular apical rotation and twist, which have been 
proven of fundamental importance for cardiac performance, might be 
influenced by alterations in spherical geometry; thereby changing the 
normal pattern of contraction (van Dalen et al., 2010; Sengupta et al., 2008). 
Myocardial  fibrosis, perhaps in combination with inadequate myocyte 
hypertrophy, might also contribute to the loss  of force of transmission 
through the LV in MR dogs (Borgarelli et al., 2007; Falk et al., 2006; Urabe 
et al., 1992; Carabello et al., 1989; Detweiler et al., 1968). Furthermore, an 
overall reduction in the volume fraction of myofibrils per myocyte unit 
volume, as seen in dogs with experimentally induced chronic MR and in 
human patients with chronic cardiac diseases, could potentially be a major  
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contributing factor to contractile dysfunction (Spinale et al., 1993; Urabe et 
al., 1992;  Zimmer  et al., 1992). In addition, downregulation and 
desensitization of the  β1-  adrenergic receptor (which is the primary 
adrenergic receptor in the normal heart) due to chronic overstimulation, as 
seen in human CHF patients (Bristow et al., 1986; Bristow et al., 1982) and 
in dogs with dilated cardiomyopathy (DCM)  (Re  et al., 1999),  could 
potentially also play a role in development of systolic dysfunction in dogs 
with advanced MMVD. 
3.3  Assessment of left ventricular remodeling and function 
Various diagnostic methods can be used when investigating LV remodeling 
and function in dogs with MMVD: 
3.3.1  Heart sounds and murmurs  
Heart murmurs 
A systolic heart murmur is a prominent  clinical finding in dogs with 
MMVD  (Häggström et al., 1995).  The cross-sectional area of the mitral 
orifice is much smaller than the cross-sectional area of the LA, which causes 
turbulence on the atrial side in systole when blood is ejected backward from 
the LV up into the LA (Figure 3). In addition, changes in valvular motion 
and function due to myxomatous degeneration alterations, might contribute 
to the production of turbulence. The kinetic energy of the regurgitant jet is 
known to be dependent on the mass (m) of the regurgitant volume, and the 
velocity (v) of the jet, according to the formula E=mv
2/2. The kinetic 
energy is transformed into heat and vibrations in the LA cavity: The 
vibrations set particles in motion, which propagate as wave-sequences of 
alternating pressure toward the chest surface, where they are accessible for 
interpretation as a murmur. 
Heart sounds 
Heart murmur assessment is one of the major objectives when performing 
cardiac auscultation, but valuable information can also be obtained from 
assessment of heart sounds. The first heart sound (S1) is concurrent with the 
closure of the atrioventricular valves, whereas the second heart sound (S2) is 
concurrent with closure of the semilunar valves. Disagreement still exists 
regarding the origin of heart sounds and two main hypotheses have been 
presented (Durand & Pibarot, 1995): According to the valvular hypothesis, 
the heart sounds are caused by transient vibrations arising when the valves  
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come to a sudden halt at the end of coaptation. Alternatively, the 
cardiohemic hypothesis assumes the heart sounds to be created by vibrations 
in the whole cardiac structure. Likely, the origin of heart sounds is best 
described by a combination of these hypotheses (Durand & Pibarot, 1995). 
Regardless which of these mechanisms that best describes the origin of heart 
sounds; LV stroke volume and function are likely involved in the 
production of heart sounds, indicating a diagnostic potential of heart sound 
assessment when investigating LV remodeling and function in MMVD dogs.  
Assessment of heart sounds and murmurs 
Sounds can be described by their frequency (unit hertz; Hz), intensity (unit 
decibel; dB) and duration (unit ms). Frequency is a physical entity, which is 
perceived by the human senses in pitch (unit mel), while intensity is 
perceived in loudness (unit phon). However, neither frequency and pitch, 
nor intensity and loudness are linearly related to each other  (Ahlstrom, 
2008). Because a perceived increase in “murmur intensity” can be caused by 
either a change in frequency or a change in absolute intensity (or both), 
  
 
 
Figure 6. Phonocardiogram (PCG) from a dog with a moderately audible murmur caused by 
MMVD. The recording is displayed in two modes, which are timed with respect to each 
other:  The upper mode shows synchronous electrocardiographic (ECG) and  
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phonocardiographic (PCG) traces; and the lower mode shows a time-frequency graph where 
different frequencies are displayed according to intensity, with high-intensity frequencies in 
red and low-intensity frequencies in blue. Note that the murmur is composed of sounds with 
frequencies up to approximately 1500 Hz. S1 - first heart sound and S2 –second heart sound.  
it might be discussed if the term “murmur intensity” is adequate for 
describing murmur severity. “Murmur audibility” is possibly a more 
appropriate terminology. 
Previous studies evaluating heart sounds and murmurs in dogs with MR 
have either been carried out by subjective assessment of auscultatory findings 
or by assessment on standard phonocardiographic (PCG) recordings 
(Häggström et al., 1995; Gould et al., 1968). Acoustic stethoscopes used for 
auscultation propagate sounds from a chest piece, which is either of 
diaphragm  type  (covered by a membrane) or of bell type  (without a 
membrane), through a tubing system into two ear pieces. In the electronic 
stethoscope, which was introduced to avoid the resonances created in the 
tubing system, the bell and diaphragm are replaced by a broad-band acoustic 
sensor and an amplifier, and the tubing and the ear pieces are replaced by 
wires and head phones. These improvements lead to enhanced sound 
quality, potentially facilitating detection of low audibility murmurs 
(Höglund, 2007).  Some information in the cardiac sound signal is 
inaccessible by standard auscultation due to physical limitations in the 
human auditory system (Selig, 1993): The human auditory system, which is 
adapted to speech, has an audible range of sounds between 20 Hz and 20 
kilohertz (kHz); with sounds in the frequency range between 1000 and 
5000 Hz being most easily perceived. This range is much higher compared 
to the range of most cardiac sounds; which often are band-limited to about 
10-1000 Hz (Ahlstrom, 2008). The interpretation of auscultatory findings 
has, furthermore, been shown highly dependent on experience and a 
considerable inter-observer variation in the ability to detect and interpret 
hearts sounds and murmurs exists (Höglund et al., 2004; Pedersen et al., 
1999; Rajakumar et al., 1999; Kinney, 1988).  
Phonocardiography (PCG), which is a quantitative graphic representation 
of cardiac sound waveforms, does not have these  limitations, and the 
technique allows visual interpretation of cardiac sounds. Previous studies in 
dogs with MMVD have shown increasing severity of MR to be associated 
with certain characteristic  features on the PCG recording: The murmur 
duration increases from early or late systolic to holosystolic, the murmur 
intensity (amplitude) increases, and there is a shift in the amplitude ratio 
between the first heart sound (S1) and the second heart sound (S2) 
(Häggström  et al., 1995).  However, manual interpretations of PCG  
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recordings cannot reveal detailed information about the cardiac sounds. The 
more recent possibility to process the recorded PCG signals by use of signal 
analysis technique has the potential to provide an objective and more 
comprehensive characterisation of heart sounds and murmurs  (Ahlstrom, 
2008); thereby potentially increasing information about the hemodynamic 
alterations occurring in the heart during different severities of MMVD.  
3.3.2  Circulating biomarkers 
The cardiac remodeling process stimulates release of various circulating 
cardiac biomarkers, and the potential of using biomarkers for diagnosing and 
monitoring dogs with cardiac diseases has recently gained interest. Besides 
the obvious utility of biomarkers for optimizing clinical management of 
MMVD dogs, biomarkers can also provide information of potential value to  
increase our understanding of the complex cardiac remodeling process.  
Cardic troponins 
Cardiac troponins are myofibril proteins, which by regulating the calcium-
mediated action between actin and myosin filaments in the myocytes are 
crucial for muscle contraction (Katz, 2001). The cardiac troponin complex 
is composed of three subunits (cardiac troponin C, cardiac troponin I, and 
cardiac troponin T), of which cardiac troponin I (cTnI) is the only one 
uniquely expressed in the myocardium (O'Brien et al., 1997).  
 
 
 
Figure 7. Schematic illustration of the cardiac troponin complex. Cardiac troponin C - cTnC, 
cardiac troponin I - cTnI, and cardiac troponin T – cTnT. 
Most cTnI is structurally bound within the myocyte, and it is released 
into the circulation only after myocyte injury (O'Brien et al., 2006). If the 
rate of cTnI release exceeds the rate of synthesis, the myocardium might 
become  partially depleted of troponins;  thereby potentially affecting  the  
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contractile function (Van der Laarse, 2002). The release of cTnI from the 
myocardium has been shown to correlate with the amount  of  myocyte 
injury, as shown in experimental animal studies (O'Brien et al., 2006; Feng 
et al., 1998; Ricchiuti et al., 1997; Smith et al., 1997), and cTnI has for this 
reason become established as a clinical biomarker of cardiac injury. The 
value of cTnI as a cardiac biomarker in dogs is supported by studies 
demonstrating increased circulating cTnI concentrations in dogs with a 
variety of etiologies of cardiac injuries (Segev et al., 2008; Linde et al., 2006; 
Oyama & Sisson, 2004; Schober et al., 2002; Schober et al., 1999). Although 
cardiac troponin assays are most commonly used in the diagnosis of acute 
cardiovascular events, a growing interest exists in evaluating troponin 
concentrations in dogs with chronic cardiac diseases. Increased circulating 
troponin concentrations have previously been shown in dogs with MMVD 
(Spratt  et al., 2005;  Oyama & Sisson, 2004), and improvements in the 
sensitivity of available cTnI assays might further increase the knowledge of 
the cardiac remodeling process in dogs. 
C-reactive protein 
Stimulation with inflammatory mediators causes a time-dependent increase 
in LV remodeling in experimentally induced heart failure models in animals 
(Bozkurt  et al., 1998),  and changes  in inflammatory pathways occurring 
locally in mitral valve leaflets have been described in dogs with naturally 
acquired heart diseases (de Laforcade et al., 2003; Mow & Pedersen, 1999). 
However, it is unknown if inflammatory  processes contribute to the 
progression of cardiac remodeling in MMVD in dogs. C-reactive protein 
(CRP), which is an acute-phase protein mainly produced in the liver, has 
been shown a valuable marker of systemic inflammatory activity in various 
diseases in dogs (Eckersall & Conner, 1988). C-reactive protein increases 
rapidly with the onset of  tissue destruction or inflammatory stimuli 
(Eckersall & Conner, 1988).  In human medicine, CRP concentration is 
reported to be related to severity of heart failure, and  to be a strong 
predictor of adverse outcome in cases of acute cardiovascular diseases 
(Sakkinen  et al., 2002;  Pye  et al., 1990).  Less is known about CRP in 
chronic cardiac diseases and previous studies of CRP in dogs with MMVD 
have shown divergent results (Tarnow et al., 2007; Rush et al., 2006).  
Matrix metalloproteinases 
The matrix metalloproteinases, the MMPs, is a family of zinc-dependent 
proteolytic enzymes known to be responsible for degeneration and 
remodeling of extracellular components  (Woessner, 1991).  The  net  
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proteolytic activities of MMPs are regulated by the tissue inhibitors of the 
MMPs, the TIMPs, which form irreversible complexes with the MMPs; 
hence blocking access to extracellular matrix substrates (Woessner, 1991). 
Various cell types within the myocardium, including myocytes and 
fibroblasts, can express and synthesize MMPs  (Hutchinson  et al., 2010; 
Coker et al., 1999; Ries & Petrides, 1995). The MMPs are secreted into the 
extracellular space in a latent form (pro MMP), which remains enzymatically 
silent until activation when an amino-terminal propeptide domain is 
removed; resulting in the ability to degradate extracellular matrix 
components.  
 
 
Figure 8. Schematic illustration of the matrix metalloproteinase (MMP) showing structural 
domains of pro MMP and active MMP (MMP-2 and MMP-9), and the transformation of the 
latent pro form into the active form. Modified from Vu & Werb (2000). 
The MMPs contain zink at their active site, they need calcium for 
stability, and they are known to be activated at neutral pH. Presence of 
disease can stimulate activity through a number of enzymatic pathways, 
resulting in excessive breakdown of extracellular components  (Spinale, 
2002; Thomas et al., 1998). The biological activation of MMPs is, however, 
still incompletely understood.  Mast cell secretory products, such as 
chymases, have been suggested capable of inducing myocardial MMP 
activation in volume-overload states in dogs with experimentally induced 
chronic MR (Stewart et al., 2003; Dell'Italia et al., 1995). In addition, MMP 
activation can be induced by the membrane-bound MMPs (MT-MMPs), 
the  extracellular  matrix metalloproteinase inducer (EMMPRIN), or by 
various cytokines (Visse & Nagase, 2003; Spinale et al., 2000; Nagase, 1997). 
Of the large family of MMPs, which includes stromelysins, collagenases,  
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gelatinases, and membrane-type MMPs, the gelatinases MMP-2 and -9 have 
been frequently reported involved in cardiac remodeling processes (Spinale 
et al., 2002). The MMP-2 and -9 possess the capacity to degrade a number 
of  interstitial proteins, including basement membrane components, 
collagenes, and laminin (Vu & Werb, 2000; Nagase & Woessner, 1999; Ries 
& Petrides, 1995). An increased expression of genes encoding MMP-1, -2, -
9 and -13 has been shown in myxomatous mitral valves in humans (Togashi 
et al., 2007; Rabkin et al., 2001; Soini et al., 2001). This is in contrast to 
findings in myxomatous mitral valves in dogs where no up-regulation of 
genes encoding MMP-2 and -9 has been shown (Aupperle et al., 2009c; 
Oyama & Chittur, 2006).  Furthermore,  the  immunohistochemical 
expression of MMP-2 in myxomatous mitral valves in dogs has been shown 
to decrease with increasing disease severity (Aupperle et al., 2009b). Human 
valve samples might have been collected earlier during disease progression; 
at the time of surgical valve replacement, and not in severe end-stage 
disease; making assessment of alterations of MMP expression during disease 
progression difficult in humans. Additionally, this complicates comparisons 
of MMP results between human and canine studies. Few studies have been 
published investigating MMP changes in other myocardial tissue structures 
than valve leaflets in people and dogs with naturally acquired mitral valve 
disease.  
3.3.3  Echocardiography 
Ultrasounds are sounds of frequencies higher than 20 kilohertz (kHz), which 
cannot be perceived by the human auditory system. Ultrasounds are created 
when piezoelectrical crystals in an ultrasonographic transducer system 
transform electrical oscillations (of varying voltages) into mechanical 
oscillations (sounds). When performing an echocardiographic examination 
(ultrasonographic examination of the heart); sound signals are transmitted by 
the piezoelectrical crystals into the thorax. Sound waves are reflected back 
to the transducer when they encounter acoustic interfaces; generating 
electrical signals which are analyzed by the ultrasonographic unit. The 
resultant monitor image provides information about cardiac dimensions and 
function, as well as valvular structure and motion. In addition, Doppler 
technology allows determination of the velocity and direction of blood 
flow, which is of value when evaluating potential valve leakages and 
intracardiac pressure gradients.  
Left ventricular anatomical dimensions and function can be assessed 
subjectively or by using various echocardiographic quantitative techniques. 
Traditional  clinical  echocardiographic assessments of the LV rely  on 1- 
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dimensional (M-mode) and two-dimensional (2D) images.  These 
assessments can, however, be flawed by assumptions of LV geometry, and 
by LV foreshortening due to image plane positioning; potentially leading to 
inaccuracies in measurements. These technical limitations  might be 
pronounced when LV morphology is changed due to presence of cardiac 
diseases (Lang et al., 2005; Kupferwasser et al., 1997). 
 
Figure 9. Illustration of the difference between 2D and RT3D image acquisition of the heart 
in the four-chamber left apical view. In the 2D mode (left), the image is acquired as a two 
dimensional slice of the heart, whereas the RT3D modality (right) allows acquisition of the 
image as a three dimensional pyramid. The benefit with the RT3D modality is that the 
volume can be rotated and cropped to visualize specific anatomic parts in three dimensions, 
which means that acquisition is less angle dependent than the 2D mode. The modality also 
allows RT3D casting of the left ventricle. 
The first real-time three-dimensional (RT3D) echocardiographic system 
was introduced in the early 1990ies (Sheikh  et al., 1991), and further  
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improvements in design and engineering have led to the recent 
commercialization of RT3D echocardiographic systems. Modern RT3D 
echocardiographic systems utilize high-frequency transducers that consist of 
more than 3000 individual crystals, which simultaneously acquire data in a 
3D pyramidal fashion in real time. The technique, which when including 
time can be referred to as four-dimensional, allows for superior anatomical 
delineation of the LV in real time. Due to the ability to manipulate the 
plane to align the true short- and long-axes of the LV, the problems with 
chamber foreshortening and oblique imaging planes can be reduced; thus 
providing  more anatomically correct views than conventional 2D 
echocardiography (Lu et al., 2008; Jacobs et al., 2006; Lang et al., 2006b). All 
voxels (i.e. volumetric picture elements)  representing intensity of 
echocardiographic reflections at a particular point in space are used in the 
LV border detection process when creating a global LV RT3D volume 
dataset. The RT3D dataset can further be divided into 17 regional segments 
by sectioning the LV from base to apex, perpendicular to the LV long-axis; 
thereby allowing regional volume assessment  (Cerqueira  et al., 2002). 
Abnormal changes in LV shape, accompanying LV dilation, can be assessed 
by  an  echocardiographically  derived sphericity index  (Di Donato  et al., 
2006;  Monaghan, 2006). A  3D echocardiographically  derived sphericity 
index has been demonstrated  an earlier and more accurate predictor of 
remodeling compared to other echocardiographic variables following acute 
myocardial infarction in human patients  (Mannaerts  et al., 2004).  The 
sphericity index is usually not included in the routine echocardiographic 
protocol when assessing LV remodeling in MMVD dogs, and this index 
might have a potential when investigating progression of remodeling in dogs 
with MMVD. 
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4  Aims of the thesis 
The general aim of this thesis was to study LV remodeling and function in 
dogs with different severities of naturally acquired MMVD using both 
recently developed and previously established diagnostic techniques in order 
to further explore the complex pathophysiology of MMVD. Increased 
knowledge of the pathophysiological processes occurring during  disease 
progression could potentially impact both clinical management and 
prediction of outcome for the individual dog in the future. 
The specific aims were to:  
 
 Investigate whether linear and nonlinear signal analyses of cardiac sounds 
could be used to assess MR severity. 
 
 Investigate  whether plasma concentrations of cTnI and CRP were 
associated with disease severity.  
 
 Investigate whether plasma activities of MMP-2 and -9 were associated 
with disease severity. 
 
 Investigate how the LV changes in shape and volume in response to 
increasing disease severity using RT3D echocardiography. 
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5  Materials and methods 
This section summarizes and comments on the material and methods used in 
the separate papers included in this thesis. More detailed descriptions of the 
procedures performed are presented in the separate papers. 
5.1  Dogs 
All studies included in this  thesis were approved by the Local Ethical 
Committee in Uppsala, Sweden. Client-owned dogs were prospectively 
recruited at the cardiology unit of the Faculty of Veterinary Medicine and 
Animal Sciences in Uppsala, and informed owner consent was obtained. 
The number of dogs occurring in more than one of the included papers is 
summarized in Table 1.  
 
  I 
n=77 
II 
n=81 
III 
n=75 
IV 
n=65 
I    53  49  (9) 
  II    75  (12) 
    III    (12) 
      IV   
 
Table 1. Number of dogs included in the different studies, and shared by two studies of the 
present thesis. Numbers within brackets represent dogs which were reexamined in study IV, 
but had been included and examined in previous studies approximately two years earlier.  
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As inclusion criteria for the studies, dogs had to either have evidence of 
MMVD or be free from physical and echocardiographic evidence of cardiac 
disease. Dogs of all breeds were allowed into the study provided that they 
fulfilled the inclusion criteria. Dogs with congenital heart disease, other 
acquired cardiovascular disorders or significant organ-related or systemic 
diseases were not included in the studies. Dogs in need of heart failure 
therapy in order to prevent clinical signs were allowed into the studies. 
Furthermore, included dogs had to have a body weight less than 15 kg: 
Occasionally, large-breed dogs have coexisting MMVD and dilated 
cardiomyopathy (DCM), and excluding larger dogs from the studies limits 
the risk of mixing multiple cardiac diseases in the study populations. In 
addition, some echocardiographic variables might be dependent on body 
size  (Bonagura & Schober, 2009). Hence, interpretation  of results was 
considered easier and more reliable in a more homogenous group of dogs. 
A majority of dogs in paper II were also included in paper III. However, 
pregnant bitches, dogs treated with glucocorticoids,  and dogs with 
detectable neoplasms were  excluded from study  III due to a possible 
influence on MMP results (Schafer-Somi et al., 2005; Loukopoulos et al., 
2003; Dollery et al., 1995); hence six dogs from study II were excluded 
from enrolment in study  III  due to ongoing glucocorticoid therapy or 
presence of small mammary tumors.  
 
5.2  Methods of examinations 
All examinations were performed without sedation in a quiet examination 
room. Dog-owners were present during all examination procedures in order 
to keep the dogs comfortable and calm. The procedures included (presented 
in the order of which they were performed in the studies) an owner-
interview (paper I-IV), blood pressure measurement (paper II-IV), physical 
examination including cardiac and pulmonary auscultation (paper I-IV), 
electrocardiographic (ECG) and PCG recordings (paper I), venous blood 
collection (paper II-III), and echocardiographic examinations (paper I-IV) 
5.2.1  Blood pressure measurement (paper II-IV) 
Blood pressure measurement was performed at the beginning of the 
examination protocol; after the dog had been adapted to the environment 
for approximately 10-15 minutes; all in order to reduce the influence of 
stress on the blood pressure results. Blood pressure was indirectly measured 
using automated oscillometric  technique.  In paper II-III, a standard  
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oscillometric device (Oscillometric Krutech VET420A, Jorgen Kruuse A/S, 
Marslev, Denmark)
  was used, whereas a  high definition oscillometric 
(HDO) device (Vet HDO monitor, S +B medVet GmbH, Babenhausen, 
Germany) was used in paper IV. For all measurements, dogs were minimally 
restrained in a standing position, and an appropriate neonatal cuff, with a 
width of approximately 40% of the tail circumference, was applied to the 
base of the tail with the artery marker placed ventrally. Once reliable 
consecutive readings were obtained, the mean of five consecutive blood 
pressure measurements was calculated (Brown et al., 2007). 
5.2.2  Assessment of heart sounds and murmurs  (paper I-IV) 
Cardiac auscultation (paper I-IV) 
Cardiac auscultation was conducted in a quiet examination room with the 
dog in a standing position. A Welsh Allyn Meditron sensor-based electronic 
stethoscope (Meditron ASA, Medi-Stim ASA, Oslo, Norway) was used for 
auscultation in all papers. The audibility of detectable heart murmurs (which 
all had to have the point of maximal audibility located over the mitral valve 
area; at the costochondral junctions between the fifth and sixth intercostal 
spaces on the left side of the chest wall) was graded on a scale from I-VI in 
accordance with established guidelines (Gompf, 1988): (Grade I murmur is 
very faint and only heard with special effort, while a grade VI is extremely 
load and accompanied by a palpable thrill on the thoracic surface). 
Signal analysis of heart sounds and murmurs (paper I). 
The electronic stethoscope was connected to a laptop computer
  (Dell
 
latitude D800 laptop, Dell Computer Corp, Limerick, Ireland) with 
accompanying acquisition software
 (Meditron analyzer, version 4.0V, Welch 
Allyn Meditron ASA, Medi-Stim ASA, Oslo, Norway), for recording of the 
PCG signals. During recording, the flat acoustic sensor of the electronic 
stethoscope was placed firmly over the point of maximal audibility over the 
mitral valve area to provide the loudest and clearest heart murmur possible. 
An  ECG  (lead II) was recorded simultaneously with the PCG. Each 
recording lasted for 10 seconds. Background noise was minimized, and the 
mouth was gently closed during the recording in panting dogs; to reduce 
ventilation artifacts.  
All recorded phonocardiographic signals were manually segmented using 
the ECG recordings as an aid for timing of the heart sounds. Four markers 
(beginning of S1, end of S1, beginning of S2 and end of S2) were 
determined for each heart cycle. Noisy or corrupted signal segments (as  
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determined by visual inspection of the data) were excluded from further 
analyses. All processing of PCG signals was performed by use of a 
mathematical computer program (MATLAB, version 7.3, The MathWorks 
Inc, Natick, Mass., USA), which was programmed to automatically derive 
seven sound variables from the segmented PCG signals. While regular 
frequency sounds can be investigated using linear techniques, non-linear 
techniques are required when investigating the complexity of sounds: Both 
linear and non-linear techniques were used in paper I. In brief: 1) The first 
frequency peak represents the dominant frequency component in the signal. 2) 
The murmur energy ratio quantifies the percentage of higher frequencies in 
the spectrum (Nygaard et al., 1993), and is defined as the energy between 
50-500 Hz divided by the energy between 20-50 Hz. 3) The  murmur 
duration>200 Hz measures the duration of sounds exceeding 200 Hz as a 
fraction of the length of systole. 4) The  sample entropy is a complexity 
measure useful for investigating dynamics  of time series  (Richman & 
Moorman, 2000).  5) The auto mutual information function represents the 
predictability of a signal 6) The energy ratio of S1 represents the normalized 
energy within the S1 segment. Since it is impossible to measure an absolute 
sound audibility, the variable was normalized against the energy in diastole 
as outlined by Durand et al (1990). 7) The energy ratio of S2 represents the 
energy within the S2 segment normalized against the energy in diastole. 
 
5.2.3  Analysis of circulating cardiac biomarkers (paper II-III) 
Blood sampling (paper II and III) 
Blood was collected by jugular venipuncture into 5-mL tubes containing 
EDTA, and the plasma was separated by centrifugation within 30 minutes of 
collection. Plasma was transferred to 1.5 mL plastic cryotubes, and all 
samples were stored at -80°C for batched analyses. The frozen plasma was 
thawed slowly at room temperature prior to analysis. 
Cardiac troponin I (paper II and III).  
Concentrations of cTnI were analyzed in duplicate using a recently refined, 
enzyme-linked immunosorbent assay (Access® Systems AccuTnI® Assay,  
Beckman Coulter, Inc., Fullerton, California, USA),  according to the 
manufacturer’s instructions. The troponin amino acid sequence is highly 
conserved across species, allowing  the use of human immunoassays for 
analysis of canine samples (O'Brien et al., 2006;Oyama & Sisson, 2004). In 
addition, an in-house validation was performed by a trained laboratory  
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technician, and the tested dilutional parallelism of canine plasma confirmed 
linearity within the assay system. The lower limit of detection for the assay 
used in the present study was 0.001 ng/mL, which is an approximately 10-
100 times higher sensitivity compared to most assays used in clinical settings 
today.  
C-reactive protein (paper II and III) 
Concentrations of CRP were analyzed in duplicate  using a previously 
validated  (Kjelgaard-Hansen  et al., 2003)  commercially available canine 
CRP ELISA assay (Tridelta PhaseTM
TRange CRP – Canine Assay, Tridelta 
Development Ltd, County Wicklow, Ireland), according to the 
manufacturer’s instructions. An in-house validation confirmed dilutional 
parallelism linearity within the assay system.  
Matrix metalloproteinase 2- and -9 (paper III). 
Plasma MMP activity was analyzed using gelatin zymography, as previously 
described  (Rajamäki  et al., 2002).  Zymography is an electrophoretic 
technique that includes a substrate copolymerized with a polyacrylamide gel 
for detection of enzyme activity. After preparation and incubation, the 
zymogram was stained and washed, and the gelatinolytic activity was 
revealed as clear bands against a darkly stained background (where the 
enzyme had degraded the substrate). For quantification of gelatin 
degradation, the gels were scanned, background grey values were subtracted, 
and the densitometric results were measured.
  Due to the risk of variation 
between each gel, the densitrometric results of each band were assessed by 
comparison with the activity of the pro MMP-2 band in standard lane on 
each gel. All zymograms were analyzed for pro- and active MMP-2 and -9 
forms.   
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Figure  10.  A zymogram from a dog showing gelatinolytic activity of the matrix 
metalloproteinases pro MMP-2 and -9 and active MMP-2 and -9, which are revealed as clear 
bands against a darkly stained background. (Courtesy of Minna Rajamäki). 
5.2.4  Echocardiographic examinations (paper I-IV) 
Dogs were gently restrained in both right and left lateral recumbency on an 
ultrasound examination table.  Echocardiographic examinations  were 
performed by use of a GE Vivid 3 ultrasonographic unit (General Electric 
Co, Stockholm, Sweden) equipped with a 5-MHz transducer in paper I-III, 
and a Philips iE33 ultrasonographic unit (Philips Ultrasound, Bothell, WA, 
USA) equipped with a 5-1 MHz transducer (for M-mode and 2D), and a 7-
2 MHz matrix transducer (for 2D and RT3D) in paper IV. Continuous 
ECG (lead II) monitoring was performed during the echocardiographic 
examinations in all studies.  
M-mode, 2D and Doppler examinations (paper I-IV) 
M-mode and 2D loops of standardized views (Thomas et al., 1993) were 
digitally stored in all studies. Screening of potential regurgitations through 
the mitral, tricuspid, aortic, and pulmonic valves was performed using color 
Doppler echocardiography. Assessment of mitral valve structures and MR 
severity was conducted from the right parasternal long-axis view and the left 
apical four-chamber view. Demonstrated MR on the echocardiogram was 
subjectively assessed as the area of regurgitant jet relative to the area of the  
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left atrium, as previously described (Olsen et al., 2003; Pedersen et al., 1996). 
The left atrial to aortic root (LA/Ao) ratio was measured as previously 
described (Hansson et al., 2002). M-mode measurements of the LV were 
performed using standard techniques (Bélanger, 2005) on images obtained 
from the right parasternal short axis view. The LV internal dimensions were 
related to body size by allometric scaling of body weight; and the values for 
the percent increases of end-diastolic left ventricular internal dimension 
(LVIDdinc) and end-systolic left ventricular internal dimension  (LVIDsinc) 
were calculated as follows: [observed dimension  –  expected normal 
dimension]/expected normal dimension x100. Expected normal dimensions 
were calculated as previously described (Cornell et al., 2004): LVIDd (body 
weight
0.294 × 1.53), and LVIDs (body weight
0.315 × 0.95). 
Real-time three-dimensional echocardiography (paper IV). 
Real-time three-dimensional (RT3D) datasets were acquired from the left 
parasternal apical four-chamber view. Series of four to seven consecutive 
ECG R-wave triggered cycles were acquired, from which four sub-volumes 
were automatically derived and integrated into one pyramidal volume; 
thereby providing a RT3D full-volume dataset of the entire LV.  
The RT3D data analyses were performed off-line using a commercial 
software
 (QLAB advanced quantification, version 7.0, Philips Ultrasound, 
Bothell, WA, USA), which displays the RT3D volume data in three 
different orthogonal planes; the two-and four-chamber views, and the short-
axis view. The orthogonal planes were all aligned interactively by use of 
color-coded conventions, according to the manufacturer’s instructions, in 
order to obtain the most anatomically correct apical views for optimal 
border delineation of the LV. Anatomic landmark definition was performed 
manually at the endocardial border in the LV cavity in the end-diastolic 
volume (EDV) frame. Automatic endocardial border tracing created a cast of 
the LV cavity, and the LV cavity border detection was then verified for 
accuracy in each view, and manually adjusted as required. The procedures 
described for the EDV frame were repeated on the end-systolic volume 
(ESV) frame. Finally, the traced borders were processed to automatically 
calculate the EDV and ESV by an algorithm model in the software. The 
cardiac volumes were indexed to body weight (volume);  EDV/kg and 
ESV/kg, based on the presumption of a linear relationship between cardiac 
volumes and body weight (Bonagura & Schober, 2009; Cornell et al., 2004). 
The RT3D long-axis length was measured in the four-chamber view as the 
distance from the endocardial apex to the mid-point of the mitral valve.   
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Figure 11. Example of a real-time three-dimensional (RT3D) volume dataset from a dog 
displayed in three orthogonal planes; the two- (upper right) and four-chamber views (upper 
left), and the short axis view (lower left), from which endocardial borders of the LV cast were 
identified, and end-diastolic and end-systolic LV volumes were obtained. The left ventricular 
3D cast is automatically divided into 17 segments according to established guidelines (lower 
right). For the purpose of this thesis, the 17 segments were further joined into three major 
segments: basal, mid and apical segments. 
Seventeen segments, defined by the American Society of 
Echocardiography  (Cerqueira  et al., 2002),  were automatically calculated 
from the LV cast, allowing regional  RT3D LV volume assessment (Figure 
2). The different segments were identified on the LV cast as fractions of the 
LV long axis length. The 17 segments were further joined into three major 
segments: Basal EDV and ESV included segments 1-6; mid EDV and ESV 
included segments 7-12; apical EDV and ESV included segments 13-17. 
Percentage contributions to the global EDV and ESV of each of the major 
regional segments, were calculated (basal, mid and apical EDV % and ESV 
%). 
Sphericity index was calculated as the RT3D-EDV divided by the 
volume of a sphere, with the sphere volume calculated as 1/6 π × L
3 (where 
L is equal to the LV long-axis length) (Di Donato et al., 2006).   
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5.3  MMVD classification systems (paper I-IV) 
Criteria for the diagnosis of MMVD included characteristic valvular lesions 
of the mitral valve apparatus (thickened and/or prolapsing mitral valve 
leaflets) and demonstrated MR on color Doppler echocardiogram 
All dogs included in the four papers were classified using an 
echocardiographic classification system: Estimation of disease severity was 
based on the obtained LA/Ao ratio and the MR jet size, and dogs were 
classified as follows: Healthy; LA/Ao < 1.5 and no MR jet, mild; LA/Ao ≤ 
1.5 and MR jet < 30%, moderate; LA/Ao > 1.5 and < 1.8 and MR jet < 
50%, and severe; LA/Ao  ≥ 1.8 and MR jet > 50%.  
The echocardiographic classification system used in paper  IV differed 
slightly from the above described classification system. There is a problem in 
interpretation of small MR jets on the color echocardiogram:  Some are 
likely to represent early stages of MMVD, whereas others may be trivial 
nonpathologic  jets  (Nakayama  et al., 1994;  Perry  & Bouchard, 1990).  
Improvements of the Doppler  technique in  new ultrasonographic units 
might increase the likelihood of detecting minimal MR signals. Hence, the 
use of the new ultrasonographic unit in  paper IV might have increased 
detection of with minimal MR of which a proportion most likely was trivial 
nonpathologic jets. Hence, dogs with minimal MR and LA/Ao < 1.5 were 
allowed into the healthy classification group in paper IV. Because minimal 
jets could create sounds influencing the sound signal variables investigated in 
paper I; dogs having minimal MR jets were classified as mild in this study. 
Some of the dogs included in paper I were also included in paper II and III, 
and the same echocardiographic classification system was applied in these 
papers. The murmurs were analyzed by sound signal analysis techniques in 
paper I, and it was therefore of interest to relate the results obtained using 
this technique to traditional auscultation assessments performed by 
veterinarians experienced in veterinary cardiology. Hence, an auscultatory 
classification system was also applied (in addition to the echocardiographic 
classification system) in paper I. For the auscultatory classification, dogs were 
divided into the following groups: normal (no audible cardiac murmur), low 
audibility  (grades I-II), moderate audibility (grades III-IV) and high 
audibility (grades V-VI) murmurs.  
5.4  Statistical analyses 
Data are presented as medians and interquartile ranges (IQR). A value of P 
< 0.05 was considered significant for the analyses, unless otherwise 
indicated.  
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The  Cuzick test for ordered groups (paper I) and Kruskal-Wallis test 
(paper II-IV) were  used to investigate overall associations between the 
investigated variables (sound signal variables, circulating biomarkers and 
RT3D echocardiographic variables) and the four MMVD severity groups. 
In variables in which a significant association was detected,  a pair-wise 
comparison was also performed by use of the Mann Whitney U-test with 
Bonferroni adjustment: Comparing four groups to each other involves six 
comparisons, resulting in a significant P-value of < 0.008. 
Unilinear (paper I-IV) and multiple regression (paper I-III) analyses were 
used to evaluate associations between the variables of interest (sound signal 
variables, circulating biomarkers and RT3D echocardiographic variables), 
and dog characteristics, HR obtained  from the echocardiogram, systolic 
arterial pressure (SAP), and M-mode and 2D echocardiographic 
measurements. In the multiple regression model, analyses were performed in 
a backward stepwise manner  (Bland, 1995),  starting with all variables 
included in the model and then removing the variable with the highest P-
value until all the remaining variables had a value of P < 0.05. All variables 
were assessed only as main effects; no interaction terms were considered in 
the model. The adjusted R
2 is defined as the percentage of the total sum of 
squares that can be explained by the regression and it also considers the 
degrees of freedom for variables added. 
In paper I, linear discriminant  analysis  (Fischer, 1936)  was used to 
investigate whether a combination  of sound variables could be used to 
distinguish severe MR from the other three severity groups. The diagnostic 
efficacy of the optimal combination  of sound variables  (which were 
obtained from the linear discriminant analysis) was further evaluated by use 
of receiver operating characteristic (ROC) curves. In particular, sensitivity, 
specificity, and area under the curve (AUC) were investigated.  
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6  Results 
This section summarizes the results from the separate papers included in the 
thesis. More detailed descriptions of the results are presented in the separate 
papers. 
6.1  Signal analysis of heart sounds and murmurs (paper I) 
The box and whisker plots in Figure 12 show the sound variables evaluated 
against the auscultatory and echocardiographic classification systems. In 
brief: The first frequency peak, and consequently the frequency spectrum, 
was shifted towards higher frequencies with more severe MR. More severe 
MR produced a murmur  with “harsher” quality, as shown by higher 
murmur energy ratio. Analysis of murmur duration > 200 Hz showed that 
murmurs shifted from early or late systolic to holosystolic with increasing 
MR severity. More severe MR showed more irregularity in flow behavior, 
as indicated by higher values of sample entropy. Lower values of auto 
mutual information  were found in dogs with severe MR, reflecting 
decreasing predictability of the sound signal with increasing signal 
complexity. The energy of S1 decreased with increasing murmur audibility, 
but showed no association with MR severity using the echocardiographic 
classification system. The  energy of S2  was found to decrease with 
increasing MR severity.   
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Figure 12. Box-and-whisker plots of seven sound variables evaluated against the auscultatory 
(left column) and echocardiographic (right column) classification systems. The upper and 
lower limits of each box represent the lower quartile and upper quartile values, respectively; 
the horizontal line within each box represents the median. The whiskers represent the extent 
of the data (1.5 times the interquartile range). Outliers are indicated (plus signs). Because of 
the low number of dogs in the clinically normal group using  the echocardiographic 
classification system, these dogs were excluded from the multiple group-wise comparison 
tests. *Values indicated by brackets differ significantly (P < 0.008).  
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Using the seven sound variables as dependent variables and dog 
characteristics (age, gender, breed and body weight), heart rate and LA/Ao-
ratio as independent variables in a multiple regression model, confirmed a 
major effect of the LA/Ao on the sound variables, but showed an absence of 
effect of the other variables included in the model. The first frequency peak 
was the sound variable giving the highest model R
2 (R
2 = 0.40, P < 0.001). 
The  linear discriminant analysis  demonstrated that  the optimal 
combination of sound signal variables (smallest variable set with the largest 
possible amount of correct detections) was the selection of energy ratio of 
S2, auto mutual information and first frequency peak, resulting in a 
sensitivity of 88% a specificity of 82% (using the echocardiographic 
classification system). The ROC curve, which summarizes the diagnostic 
performance of a test, had an AUC of 0.89 for this combination. 
6.2  Analysis of circulating biomarkers (paper II-III) 
6.2.1  Cardiac troponin I (paper II-III). 
Detectable concentrations of cTnI were found in 67 % of the included dogs. 
Plasma cTnI showed either barely detectable concentrations, or 
concentrations below the lower limit of detection for the assay  in the 
healthy dogs, but cTnI concentration increased with increasing MMVD 
severity. Uni- and multiple regression analyses showed a major effect of age, 
CRP concentration, HR, and LVIDdinc% on cTnI concentration, and the 
final multiple regression model had an adjusted R
2 of 0.63 (P< 0.0001). Age 
was the variable most strongly associated with cTnI in the unilinear analyses 
(R
2 = 0.50, P < 0.0001). Because of the strong association between age and 
cTnI concentration, further investigations were performed within the four 
different MMVD groups: Concentration of cTnI increased significantly with 
increasing age in the mild MMVD group (R
2 = 0.47, P < 0.0001), which 
included nearly 50% of the dogs in the study population, and in the severe 
MMVD group (R
2 = 0.26, P = 0.018).  
6.2.2  C-reactive protein (paper II-III) 
Detectable concentrations of CRP were found in all included dogs. 
No significant difference was shown between CRP concentration and the 
four MMVD severity groups, but CRP concentration was associated with 
cTnI concentration, breed, and systolic blood pressure  in the multiple 
regression analysis. However, the regression model had a comparably low 
model R
2 (R
2 = 0.24, P < 0.0001), and slight modifications in the order the  
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variables were removed in the backward analysis process had a comparably 
large effect on the outcome, indicating an unstable model.  
6.2.3  Matrix metalloproteinase 2- and -9 (paper III). 
Zymography of the plasma samples revealed gelatinase expression of pro 
MMP-2 and pro MMP-9 activities in all included dogs, and active MMP-9 
was found in 85 % of the dogs. Active MMP-2 could not be detected in the 
study population. No overall significant differences were found between 
MMP activity, and the four MMVD severity groups. 
Uni- and multiple regression analyses showed that pro MMP-9 decreased 
with decreasing SAP, and was higher in male dogs than in female dogs. 
However, the final multiple regression model was weak with an adjusted R
2 
of 0.14.  Systolic arterial pressure  (SAP)  was the variable most strongly 
associated with pro MMP-9 in the unilinear analyses (R
2  =  0.10,  P  < 
0.0037).  
Uni-  and multiple regression analyses showed that active MMP-9 
decreased with increasing LVIDsinc, and with decreasing cTnI, SAP, and age 
(the latter did only reach a significant level in the unilinear analysis). The 
final multiple regression model had an adjusted R
2 of 0.29. Left ventricular 
end-systolic dimension was the variable most strongly associated with active 
MMP-9 in the unilinear analyses (R
2 = 0.11, P = 0.0039). 
Pro MMP-2 activity was not significantly associated with any of the 
investigated variables in the uni- or multiple regression analyses. 
6.3  Assessment of left ventricular volume and shape (paper IV). 
Dogs with severe MMVD had higher values of EDV, ESV, long-axis 
length, and sphericity index, compared to dogs in the other MMVD 
severity groups  (Figure 13). Dogs with moderate MMVD had higher 
contribution of the mid EDV segment to the global EDV, compared to 
values in dogs with mild MMVD. 
Unilinear regression analyses showed that global and regional EDV and 
ESV, long-axis length, and sphericity index increased with increasing disease 
severity, as indicated by increasing LA/Ao ratio, LVIDdinc %, and LVIDsinc %. 
In addition, SAP decreased with increasing EDV and ESV. Even though all 
three regional LV segments contributed to the increase in global EDV and 
ESV with increasing MMVD severity, the mid EDV contributed the most 
to the global EDV increase. Assessing regional contribution to changes in 
LV shape; sphericity index was associated with decreasing percentage  
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contribution of basal EDV, and increasing percentage contribution of apical 
EDV to global EDV.  
 
 
 
Figure 13. Left ventricular end-diastolic casts obtained from the RT3D dataset from a healthy 
dog (left) and a dog with severe MMVD (right). The diseased heart has a more rounded left 
ventricular appearance (and thereby an increased sphericity index), in addition to a globally 
increased left ventricular volume.  
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7  General discussion  
 
The cardiac remodeling process in dogs with MMVD is highly complex, 
with different processes occurring  simultaneously, and most likely with 
varying degrees  of  contribution  during disease progression. Some results 
from the studies included in the present thesis might primarily be important 
for understanding the pathophysiological changes occurring during the LV 
remodeling process, whereas others could potentially  be more directly 
valuable for improving the assessment of MMVD severity; and hence, the 
clinical management of affected dogs.   
7.1  Changes in left ventricular morphology and function 
7.1.1  Heart sounds and murmurs 
The murmur-audibility has previously been shown to increase with severity 
of MMVD (Häggström et al., 1995), but signal processing of murmurs has, 
to the best of the author’s knowledge, never been applied for assessment of 
MR in any species. Quantification of MR can provide valuable information 
about LV remodeling status and function in MMVD dogs.  In paper I, 
duration of systolic frequency contents exceeding 200 Hz was nearly 
nonexistent in normal dogs (recorded cardiac acoustic signals can be 
obscured by respiratory sounds, rumbling sounds from the stomach, friction 
rubs, and ambient sounds; explaining the existence of detectable sound 
signals in systole; even in the absence of a systolic murmur), but increased in 
duration with increasing MR severity: Dogs with moderate to severe 
MMVD had long systolic durations of frequencies exceeding 200 Hz. These 
findings indicate a maintained energy in the MR jet in late stages of the 
disease. In the typical MMVD dog, the maximal systolic flow velocity of the 
MR remains comparably constant until late stages of the disease when it 
might  decrease  (Olsen  et al., 2010);  likely as a consequence of altered  
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intracardiac pressure gradients due to LV systolic dysfunction and  increased 
intraatrial pressure. But even though LV systolic function worsens in late 
stages of the disease (Borgarelli et al., 2007), sufficient function remains to 
eject a large MR volume into the LA; thus generating a holosystolic high 
frequency murmur. The large retrograde stroke volume in dogs with more 
severe MR creates a murmur of “harsher” quality and with higher 
frequency content, indicated by an increase in the first frequency peak, and 
murmur energy ratio, in these dogs. In addition, the results from the non-
linear investigations using sample entropy and auto mutual information 
indicate that more severe MR has more irregularity in the flow behavior, 
and thus less predictability in the signal. 
The intensity of S1 has commonly been regarded to increase with 
increasing disease severity in dogs with MMVD. Remarkably, in paper I, 
the energy of S1 was shown to decrease with increasing murmur audibility, 
and showed no association with MR severity using the echocardiographic 
classification system. Merging of the S1 with the forceful murmur might 
give an impression of increased audibility of the S1 when subjectively 
assessed by cardiac auscultation, possibly explaining previous reports of 
increased S1 audibility with increasing MR severity (Gould et al., 1968). 
The relative intensity between S1 and S2 has been shown to change with 
increasing MMVD severity when manually measured on PCG recordings 
(Häggström et al., 1995), but an objectively performed study of potential 
heart sound alterations caused by MR has, to the author’s knowledge, never 
been published. A possible mechanism explaining the decrease in S1 energy 
with increasing murmur audibility is that the degenerated valve might 
influence the vibrations involved in the origin of S1. A reduction in LV 
systolic function with disease progression could potentially also influence the 
S1. The energy of S2 was found to decrease with increasing MR severity, 
which is in accordance with a previous PCG study in MMVD dogs 
(Häggström et al., 1995). The intensity of S2 is reported to primarily depend 
on the rate of change in the pressure gradient across the aortic valve at 
closure (Sabbah & Stein, 1976), and a diminished forward stroke volume 
(Kittleson & Brown, 2003) might explain the decreased energy ratio of S2 
seen in dogs with increasing severity of MR.   
7.1.2  Circulating cardiac biomarkers 
Cardiac troponin I 
To the best of the author’s knowledge, this was the first study exclusively 
designed to investigate the  association between cTnI concentration and  
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MMVD severity in dogs. Potential effects of CRP and dog characteristics on 
cTnI concentration were controlled for in the study. Plasma cTnI 
concentration was  found to increase with increasing MMVD severity, 
which indicates ongoing myocyte injury in a chronic remodeling process. 
However, the exact cause of such processes remains unknown. Intramural 
myocardial arteriosclerosis; with loss of compliance in the arterial vascular 
walls due to luminal narrowing, has been described in dogs in CHF due to 
MMVD (Falk et al., 2010; Falk et al., 2006). These changes might affect the 
vascular supply to the myocardium; ultimately promoting regional hypoxia 
and myocyte death  (Sabbah  et al., 1995;  Detweiler  et al., 1968).  The 
arteriosclerotic changes have  furthermore been shown associated with 
myocardial fibrosis in MMVD  dogs (Falk et al., 2010;  Falk et al., 2006; 
Detweiler, 1989;  Jönsson, 1972;  Detweiler  et al., 1968)  supporting  the 
hypothesis of arteriosclerosis-induced myocyte death  as a causative factor in 
development of myocardial fibrosis in MMVD dogs. Yet, a reversed 
scenario is possible: Remodeling of the ECM  might increase the amount of 
myocardial fibrosis, which by reducing the capillary density in the 
myocardium; and thereby, the oxygen diffusion distance, damage myocyte 
integrity (as seen in dogs with experimentally induced CHF) (Sabbah et al., 
1995).  The oxygen demand might furthermore be increased in the 
hypertrophied myocardium; potentially lowering the threshold for 
myocardial hypoxia (Piano et al., 1998). Such a scenario, if present, is likely 
to occur intermittently or be of subclinical character in the clinical situation 
because most dogs with MMVD do not present typical changes indicative of 
hypoxia on the ECG. Myocyte loss can also be a result of programmed cell 
death (apoptosis) in the hypertrophied myocardium in dogs (Sharov et al., 
1996), potentially due to increased levels of aldosterone, norepinenephrine, 
AII, and various inflammatory mediators (Ferrari et al., 1998; Sabbah et al., 
1995): However, it is not established if their concentrations are sufficiently 
high to promote direct myocyte necrosis in the failing heart in dogs with 
MMVD.  
Paper II described that the cardiac release of cTnI started in the early 
stages of MMVD in dogs. The true biological half-life of cTnI has been 
reported to be approximately 70 min in dogs (Jaffe et al., 1996). Thus, the 
increase in cTnI concentration was most likely due to an ongoing release of 
cTnI caused by a continuous remodeling process, rather than an acute 
process. Minimal myocardial cTnI loss might be of minor importance for 
contractile function in the short term. However,  chronic myocardial 
degradation and long-term loss of myocardial troponins has been suggested 
to affect LV contractile function (Van der Laarse, 2002).  
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A strong association between age and cTnI concentration was found, 
indicating that age causes myocardial changes leading to cTnI leakage. In 
fact, age was the variable most strongly associated with cTnI concentration. 
An association between age and cTnI has previously been reported in 
healthy dogs (Oyama & Sisson, 2004), people (Venge et al., 2003), and rats 
(O'Brien et al., 2006). Intramural arteriosclerotic changes have been shown 
associated with normal aging in dogs, potentially causing defects in the 
oxygenation potential in the myocardium in elderly dogs; and thereby 
myocyte injury or loss  (Whitney, 1976;  Jönsson, 1972;  Detweiler & 
Patterson, 1965). A marked myocyte loss has been reported to occur with 
age in humans (more evident in males) potentially explained by ischemic 
injuries  (Olivetti  et al., 1995;  Olivetti  et al., 1991).  A  certain degree of 
cardiac fibrosis has also  been seen in the aging heart in various species 
(Lakhan & Harle, 2008; Thomas et al., 2000; Villari et al., 1997; Klima et al., 
1990; Mukherjee & Sen, 1990), but the actual prevalence of myocardial 
fibrosis in elderly dogs is not known. Because changes associated with 
normal aging might be difficult to separate from those caused by cardiac 
diseases, the effect of age on cTnI needs consideration when evaluating this 
biomarker in dogs. Hypothetically, age-related changes in cardiovascular 
structure and function might reduce the ability to compensate for cardiac 
diseases in elderly individuals.  
C-reactive protein 
Concentration of CRP was not associated with MMVD severity in the 
examined dogs. All dogs had detectable circulating concentrations of CRP, 
but based on previous reported normal variations in healthy dogs (Mischke 
et al., 2007; Kjelgaard-Hansen et al., 2003) dogs with clinically important 
systemic inflammation were not represented in the study population; as all 
dogs had CRP concentrations within the normal range.  A  multiple 
regression model showed significant associations between CRP 
concentration and cTnI concentration, breed, and SAP. However, a 
comparably low model R
2, in combination with the knowledge that CRP 
can increase due to tissue destruction or inflammatory stimuli in other 
organs, suggest that CRP is not a sensitive biomarker for evaluation of 
MMVD remodeling in dogs. Yet, in order to further evaluate the role of 
inflammation in the pathogenesis of MMVD, further investigations, 
including other markers of inflammation, are needed.  
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Matrix metalloproteinase 2- and -9 
Changes in the myocardial structure with loss of the fine collagen weave 
surrounding the myocytes might occur due to selective induction of MMPs 
(Spinale, 2002; Woessner, 1991). Previous reports on MMPs in dogs with 
naturally acquired MMVD have focused on changes in the mitral valve 
leaflets (Aupperle et al., 2009a; Aupperle et al., 2009c; Oyama & Chittur, 
2006). To the best of the authors’s knowledge, paper III is the first study 
exclusively designed to investigate circulating activity of MMPs in different 
severities of MMVD in any species. Circulating activity of pro– and active 
MMP-2 and -9 were investigated, and activity of MMP-9 was shown to 
decrease with increasing LVIDsinc % and decreasing SAP. Hence, activity of 
MMP-9 was, in contrast to cTnI,  linked to variables  reflecting systolic 
function, but not to variables reflecting LV dilation; indicating that MMP-9 
and cTnI might reflect different aspects of the complex cardiac remodeling 
process in MMVD dogs. The MMVD severity classification system used in 
this thesis did primarily reflect degree of left-sided cardiac dilation; possibly 
explaining  the lack of significant differences between MMP activity  and 
MMVD severity groups. Changes in activity could, moreover, possibly be 
intermittently up-  or down-regulated during the disease progression 
(potentially counterbalanced by the TIMPs), which could create a unique 
MMP profile in the single dog at a given time, not reflected in group-wise 
comparisons including many dogs.  
Down-regulation of MMP-9 has previously been suggested involved in 
the pathogenesis of naturally occurring MMVD in dogs (Aupperle et al., 
2009c).  A normalization or down-regulation of  MMP activity has 
furthermore been described to occur in dogs with sustained volume 
overload after experimentally induced cardiac failure  (Khan  et al., 2004; 
Nagatomo  et al., 2000).  Such a down-regulation might protect against 
uncontrolled progressive dilation, by reducing extracellular matrix 
breakdown and enhance fibrosis development (Gill et al., 2006; Anne et al., 
2005; Peterson et al., 2001; Blaustein et al., 1995; Dollery et al., 1995); a 
hypothesis strengthened by the finding of decreased activity of MMP-9 with 
increasing amounts of fibrosis in atrial appendages in human patients with 
mitral valve disease (Anne et al., 2005). An increased expression of genes 
encoding MMP-1 and -9, in combination with decreased expression of 
genes controlling synthesis of ECM components, was suggested responsible 
for the loss of collagen within the ECM seen in a dog model four months 
after MR induction (Zheng et al., 2009). As stated by the authors of that 
study; a time point of four months post MR induction might have been 
early in the time course, and fibrosis (as commonly seen in dogs with severe  
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MMVD of naturally acquired origin (Falk et al., 2010; Falk et al., 2006))  
and a changed MMP profile might have ensued at a later stage of MR 
(Zheng et al., 2009).   
Active MMP-9 was in paper III shown most strongly associated with the 
echocardiographic variable LVIDsinc, which (based on the finding in the 
present thesis and in previous published articles) has been shown to increase 
in dogs with more severe MMVD;  indicating  systolic dysfunction 
(Borgarelli et al., 2007). An increased amount of myocardial fibrosis might 
influence the Frank-Starling mechanism (Komamura  et al., 1993), and 
disable an optimal transduction of contractile force generated by the 
myocytes in systole. This could possibly explain the association between 
systolic dysfunction and MMP activity. However, identification of systolic 
dysfunction is challenging in dogs with MMVD: The retrograde ejection of 
LV stroke volume, which starts already in early systole (Lord, 1974; Eckberg 
et al., 1973); reduces afterload, whereas the increased volume load leads to 
an increased preload (O'Gara et al., 2008). Depending on severity of MR, 
these changes lead to normal to hyperdynamic LV contraction, even in the 
presence of intrinsic myocardial dysfunction. Many of the commonly used 
echocardiographic indices for evaluating systolic function, such as the 
ejection phase indices (ejection fraction and shortening fraction) are, besides 
being dependent on intrinsic contractility, also known to be influenced by 
hemodynamic load and sympathetic tone, which potentially mask significant 
myocardial dysfunction in dogs with MR. Assessment of LV end-systolic 
dimension has been suggested to better reflect systolic dysfunction in the 
presence of MR (Borgarelli et al., 2007;  Borow et al., 1980). The end-
systolic dimension increases as the systolic function declines; despite 
increasing retrograde LV stroke volume into the low resistance LA (O'Gara 
et al., 2008). But if the LV contractile function is preserved, the fully 
compensated LV will shorten to an almost normal end-systolic dimension 
(Bonagura & Schober, 2009). The more recently introduced tissue doppler 
imaging (TDI) technique has been considered comparably independent of 
loading conditions, but recent studies suggest that this technique is affected 
by loading condition and sympathetic tone activity to a greater extent than 
previously expected, which might limit the additional informative value 
obtained from this technique, compared to when using  LVIDsinc(Tidholm et 
al., 2009). Although myocardial systolic function declines with progression 
of disease, the remodeling process allows the LV to retain a relatively well 
preserved forward cardiac pump function even in advanced MMVD 
(Kittleson  et al., 1984):  Increased pulmonary blood volume, and not 
decreased forward stroke volume, has been shown to be the main cause of  
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abnormal cardiopulmonary function in dogs with MMVD (Eriksson et al., 
2010). This finding corresponds with the clinical observation that dogs with 
severe MR suffer more commonly from pulmonary congestion and edema 
(which cause respiratory signs) than signs caused by reduced forward cardiac 
output (lethargy, weakness, exercise intolerance) (Olsen et al., 2010).  
Activity of MMP-9  decreased  with  decreasing SAP in paper III. 
Reduced forward stroke volume due to MR (Kittleson & Brown, 2003) 
and LV systolic dysfunction (Borgarelli et al., 2007), might contribute in 
lowering SAP in dogs with more severe MMVD (as SAP is determined by 
cardiac output, which is the product of stroke volume and systemic vascular 
resistance). However, all dogs in paper II-IV had SAP within, or close to, 
normal reference ranges, indicating that the LV forward systolic function 
does not decline dramatically, and that regulatory mechanisms contribute in 
maintaining acceptable SAP even in the severe stage of the disease. The SAP 
did not differ significantly between dogs in the different MMVD severity 
groups in paper III, although dogs with more severe disease tended to have 
lower SAP than dogs with less severe disease.  Such a tendency  has 
previously been  described in dogs with MMVD  (Moonarmart, 2008). 
Significantly lower SAP (using a conservative P value; P < 0.008) in dogs 
with severe MMVD compared to dogs in the other MMVD severity groups 
were shown in paper IV. Data obtained by the HDO device used in paper 
IV might be more accurate and precise than data obtained by a standard 
oscillometry device (Schmelting et al., 2009). In addition, a faster acquisition 
time of the HDO device could have reduced the influence of stress on the 
results in paper IV. All in all; these improvements in technology might have 
uncovered differences in SAP between MMVD severity groups in paper IV, 
which could not be shown in paper III using standard oscillometry. 
Circulating activities of MMP-2 and -9 have been reported to increase in 
human patients with acute cardiovascular diseases  (Hojo  et al., 2001; 
Inokubo et al., 2001), which contrasts the findings in the MMVD dogs in 
paper III. Hence, type, degree, and duration of extracellular stimuli in 
different cardiac diseases likely affect the MMP profile within the failing 
myocardium, as previously suggested (Spinale, 2002). Pro MMP-2 was not 
significantly associated with any of the investigated variables in paper III, 
and  active MMP-2 could not be detected in the study population.   
Consequently, based on these results, and previously published results 
(Aupperle et al., 2009c; Oyama & Chittur, 2006), MMP-2 is possibly not 
playing a central role in the progression of naturally acquired MMVD in 
dogs.   
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7.1.3  Left ventricular volume and shape 
To the best of the authors’  knowledge, this is the first RT3D 
echocardiographic study designed to investigate  how the LV changes in 
global and regional volume and shape in response to different severities of 
naturally acquired mitral valve disease  in any species.  The cardiac 
remodeling  process  progresses slowly, but inexorably, over years as the 
degree of MR worsens (Lord et al., 2010). However, the results from paper 
IV clearly suggest that a large LV volume expansion does not occur before 
dogs have reached the more severe stage of the disease:  Group-wise 
comparisons of global and regional EDV and ESV (using a conservative P 
value; P < 0.008) could only separate dogs with severe MMVD from other 
MMVD severity groups. The regurgitant fraction (the percentage of stroke 
volume ejected into the LA), which is regarded the major determinant 
factor of cardiac size and disease severity, is higher in dogs with severe 
disease compared to in dogs with mild to moderate disease (Kittleson & 
Brown, 2003); likely explaining the more pronounced LV dilation in dogs 
with severe MMVD in paper IV. This result is in accordance with previous 
studies using radiography, or circulating B-type natriuretic peptide (BNP) 
(which is released from the myocytes in response to increased LV 
myocardial stress) to investigate the progression of volume overload before 
onset of CHF in dogs with MMVD (Lord et al., 2010; Tarnow et al., 2009).
 
The results reflect a more drastic increase in volume overload in dogs with 
close proximity to CHF. The rate of change of LV volumes in individual 
dogs could not be assessed in paper IV because the dogs were not followed 
over time.  
The LV mid segment was the regional segment increasing the most in 
EDV and ESV with increasing disease severity in dogs included in paper IV. 
Potentially, LV anatomy allows more pronounced myocardial stretch in the 
mid segment, while the apical and basal segments are more restricted to LV 
expansion, due to supporting structures such as the AV annular ring in the 
basal segment. In addition, the LV has a smaller diameter in the apical 
region than in the mid-segment, and because the pressure within the LV at a 
given moment is the same, regardless location, wall stress is smaller in the 
apical than in the mid segment, according to the law of LaPlace. This, in 
turn, could lead to lesser tendency for dilatation of the apex. The percentage 
contribution of the mid segment to global EDV was only significantly 
higher in dogs with moderate MMVD compared to values in dogs with 
mild MMVD. The lack of significant differences between severe MMVD 
dogs and other severity groups suggests a change in LV shape in the  
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moderate stage; leading to increased percentage contribution of the mid 
segment.   
Results from paper IV on LV sphericity index indicate that the LV shape 
changes from elliptical to more globular in response to chronic volume 
overload. An increase in global LV sphericity might allow myocardial 
adaptation to abnormal regional wall stress. However, an increase in LV 
sphericity might also disrupt normal mitral annular geometry; and as a result; 
increase the production of secondary MR (Hung et al., 2004; Lapu-Bula et 
al., 2002;  Otsuji  et al.,  1997;  Kono  et al., 1992).  Accordingly,  a more 
globular LV shape might, to some degree, protect the myocardium from the 
abnormal wall stress caused by the LV volume overload, but at the same 
time contribute to a further increase in volume overload by stimulating 
secondary MR. 
Assessing regional contribution to changes in LV shape, sphericity index 
was shown associated with decreasing percentage contribution of basal EDV 
to global EDV and increasing percentage of apical EDV. Rounding of the 
LV base with increasing MMVD severity, results in a better fit of the basal 
EDV into the  sphere; and this change in LV shape leads to a reduced 
percentage contribution of the basal EDV to the global EDV. The apical 
EDV segment in the elliptical LV has less contact with the theoretical 
sphere, compared to in the spherical LV; resulting in increased percentage 
contribution of the apical EDV to the global EDV with increasing sphericity 
index. Although the mid segment was the segment increasing the most with 
increasing LV dilation, no association was shown between sphericity index 
and percentage contribution of mid EDV to the global EDV; most likely 
reflecting that only minor changes occur in the LV mid segmental outlining 
with increasing MMVD severity. These findings, in combination with the 
result that the long-axis length increased with increasing disease severity, 
suggest that although the LV changes into a more globular shape with 
increasing MMVD severity, the shape does not end up as an absolute 
sphere.  
7.2  Possible clinical implications 
7.2.1  Heart sounds and murmurs 
The sound signal content of the murmur changes with severity of MR, 
which leads to increased audibility of the murmur. Hence, a typical dog (a 
small-breed dog, which at mature age has developed a systolic murmur of 
maximal audibility over the mitral valve area) previously diagnosed with 
MMVD by echocardiography, might be monitored by murmur assessment  
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until a high-audibility murmur has been diagnosed or overt signs of CHF 
have developed. Correct identification of severe MR would be of particular 
interest for clinicians when performing risk assessment or when deciding if 
special care and more extensive examinations are required. Because 
characterization of acoustic findings has been shown highly dependent on 
the experience of the examiner, and a considerable inter-observer variation 
exists (Höglund et al., 2004; Pedersen et al., 1999; Rajakumar et al., 1999; 
Kinney, 1988); improvement in sound analysis tools is desirable. A majority 
of the sound variables investigated in paper I was  dependent on MR 
severity, which demonstrates a diagnostic potential. The different 
investigated sound variables reflect different fractions of the heart sounds and 
murmurs; and a combination of variables was shown to optimize detection 
of severe MR. 
The traditional auscultation technique will remain important in the near 
future because clinically practical tools for mathematical sound analyses 
procedures do not yet exist.  Advances in the technical devices, making 
signal analysis techniques clinically applicable, are warranted: A future 
introduction of an innovative “intelligent stethoscope” with decision 
support abilities (Ahlstrom et al., 2006), could hopefully offer a simple and 
cost-effective method for monitoring dogs with MMVD.  
7.2.2  Circulating cardiac biomarkers 
Both cardiac and extracardiac diseases have the potential to induce myocyte 
injury, and due to the non-specific origin of myocardial damage; assessment 
of circulating concentrations of cTnI is unlikely to perform well  when 
establishing the diagnosis of MMVD.  Although  the  circulating cTnI 
concentration increased with increasing MMVD severity, a considerable 
overlap existed between the different severity groups; hence, cTnI 
concentration  alone  cannot  effectively  be used for MMVD severity 
assessment. Establishing prognosis in a single dog with MMVD is difficult, 
and myocardial changes reflected by high sensitivity cTnI analyses might 
provide prognostic information. High sensitivity assays have shown 
previously immeasurable troponin concentrations in humans with 
cardiovascular diseases, to be highly predictive of  future cardiac events 
(Eggers et al., 2009; Schulz et al., 2007). Increased cTnI concentrations have 
furthermore been shown linked to a worse outcome in dogs with 
cardiomyopathy (Oyama & Sisson, 2004). The studies in papers II and III 
were  not designed to evaluate the prognostic value of the circulating 
biomarkers, and future longitudinal studies are needed for that purpose.   
Different biomarkers can provide information about different aspects of  
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cardiovascular diseases, and a combination of  troponin analyses  with 
analyses of other biomarkers, such as  BNP, has the  potential to further 
improve the prognostic assessment of the individual cardiac patient (Latini et 
al., 2007;  Jernberg  et al., 2002).  However, effect of age on cTnI needs 
consideration when assessing cTnI in canine cardiac patients.  
Concentration of CRP has  previously been reported associated with 
severity of CHF (Pye et al., 1990), and shown capable of predicting acute 
cardiovascular events in human patients (Sakkinen et al., 2002). The lack of 
association between CRP concentration and MMVD severity in the 
examined dogs in paper II indicates a lack of diagnostic value of  CRP 
analyses in MMVD dogs. However, a potential value of CRP (preferably 
when used in combination with other biomarkers) for predicting outcome 
in MMVD dogs, cannot be excluded.  
Whereas established cardiac biomarkers; such as the natriuretic peptides, 
primarily reflect ventricular wall stretch (and thereby indirectly volume 
overload), MMP-9 was shown associated with variables reflecting systolic 
function in paper III. Hence, MMP-9 might provide additional information 
to other biomarkers used when trying to explore the complex cardiac 
remodeling process in MMVD dogs. However, the significant associations 
found between MMP-9 activity and some of the investigated variables were 
rather weak and circulating activities of MMP-2 and -9 cannot be regarded 
as valuable diagnostic biomarkers in clinical practice based on the results 
from paper III. Identification of the specific portfolio of MMPs and TIMPs 
expressed within the failing myocardium could potentially improve future 
treatment strategies for individuals with chronic cardiac diseases; aiming to 
prevent or slow down the disease progression, instead of only improving 
clinical signs at the end of the remodeling process. 
7.2.3  Left ventricular volume and shape 
The results from the RT3D LV volume assessment of dogs in paper IV 
showed prominent LV volume expansions only in dogs with more severe 
MMVD. Left heart chamber enlargement has been characterized by a slow 
phase of steadily progressing MMVD until about 6 to 12 months before 
onset of CHF, when rate of change of enlargement is fast (Lord et al., 2010). 
Routinely  performed volume assessment could potentially improve 
prediction of outcome for individual dogs; allowing risk-detection of 
forthcoming CHF at an earlier stage. The study design of paper IV did not 
include longitudinal follow-up  studies; hence, the value of RT3D 
measurements in predicting outcome could not be evaluated. In order to 
use RT3D LV volumes in clinical practice, normal reference values need to  
  64 
be established. However, although clinical use of modern 3D systems is 
boosted by advances in computer technology; reducing acquisition and post 
processing time, a shortcoming of the RT3D technique still lies in the fact 
that it is more time consuming compared to traditional echocardiographic 
techniques.   
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8  Conclusions 
 Linear and nonlinear analyses of cardiac sounds can be used to assess MR 
severity, as shown by the associations found between many of  the 
investigated sound variables and MR severity: More severe MR 
produces a murmur of “harsher” quality, longer duration, and with more 
complexity in the signal. The energy of S1 was not associated with MR 
severity (assessed by echocardiography), whereas the energy of S2 
decreased with increasing MR severity.  
 
 Circulating cTnI concentration increased with increasing disease severity, 
however, the effect of age on cTnI needs consideration when evaluating 
chronic cardiac remodeling in dogs using a high sensitivity cTnI assay. 
Circulating CRP concentration was not associated with disease severity.  
 
 The MMP-2 and -9 activities were not associated with MMVD severity 
groups (which were mainly based on severity of volume overload). 
However, MMP-9 activity decreased with worsening systolic function. 
Based on the findings from this thesis, MMP-2 might play a minor role 
in MMVD in dogs. 
 
 Chronic volume overload in dogs with MMVD changes LV geometry. 
The RT3D  examinations showed prominent LV volume expansions 
only in dogs with more severe MMVD.  The mid LV segment 
contributed  the most to the global volume  increase. The LV shape 
changed from elliptical to more globular in response to increasing 
volume overload, with the basal and apical segments contributing the 
most to the increase in sphericity.  
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9  Implications for future research 
 Further studies, investigating the potential of signal analysis technique for 
analysis  of cardiac sounds in dogs with various cardiac diseases, are 
warranted. 
 
 High sensitivity cTnI assays, capable of detecting subtle myocardial 
changes, could be valuable for future prospective  studies. Preferably, 
cTnI  could be combined  with other biomarkers  in order to better 
predict long-term outcome. 
 
 Further investigations,  including other markers of inflammation  than 
CRP, could be conducted in order to further evaluate a potential role of 
inflammation in the pathogenesis of MMVD and CHF development.  
 
 An important future direction is to characterize the specific portfolio of 
MMPs and TIMPs  in the myocardium, and furthermore, investigate 
their interactions in dogs with MMVD.  
 
 Assessment of LV volume and shape could potentially allow early 
detection of dogs at risk for rapid progression into congestive heart 
failure. Longitudinal follow-up studies are needed to investigate whether 
RT3D echocardiography could improve prediction of outcome in dogs 
with MMVD compared to conventional echocardiography. 
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10 Populärvetenskaplig sammanfattning 
Kronisk hjärtklaffsdegeneration är den vanligaste hjärtsjukdomen hos hund, 
och den  drabbar framför allt  hundar av små till medelstora raser från 
medelåldern och uppåt i ålder. Sjukdomen leder till att hjärtklaffen mellan 
vänster förmak och kammare (mitralisklaffen) förändras i struktur och får ett 
onormalt rörelsemönster. Sjukdomen liknar mitralisprolaps-syndromet hos 
människor.  Eftersom klaffen inte längre kan sluta tätt, börjar blod läcka 
tillbaka upp i förmaket när hjärtat kontraheras, istället för att enbart pumpas 
ut i stora kroppspulsådern.  Turbulens  i blodet uppstår i samband med 
klaffläckaget, vilket ger upphov till ett blåsljud som kan höras när man 
lyssnar på hjärtat med stetoskop. Graden av turbulens styrs både av graden av 
klaffläckage och av vänster kammares funktionsduglighet. För att 
kompensera klaffläckaget ökar volymen i vänster förmak  och kammare, 
liksom vänster kammares muskelmassa.  Hundar med kronisk 
hjärtklaffsdegeneration kan ha sjukdomen under flera år  utan att visa 
sjukdomstecken. Hos vissa hundar blir dock återflödet till förmaket så 
kraftigt att hjärtat inte längre klarar att kompensera för otätheten, och 
hundarna drabbas av hjärtsvikt.  
Syftet med avhandlingen var att beskriva hur vänster kammare förändras 
hos hundar med olika långt framskriden hjärtklaffsdegeneration genom att 
använda digital analys av blåsljud och hjärtljud, specifika markörer som kan 
mätas i blodet och modern ultraljudsteknik.  
I avhandlingen användes för första gången hos något djurslag digital 
signalanalysteknik för att undersöka förändringar i blåsljudets och 
hjärttonernas karaktär vid olika långt framskriden kronisk 
hjärtklaffsdegeneration. Tekniken möjliggör även analys av ljudsignaler som 
inte kan uppfattas av människans hörsel. Resultaten visade att hundar med 
kraftigt klaffläckage hade blåsljud med högre frekvensinnehåll, duration och  
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komplexitet, jämfört med hundar med mildare klaffläckage. Även 
hjärttonernas energiinnehåll påverkades av graden av klaffläckage.  
Förändringar  i hjärtats volym och vikt bidrar till att olika substanser 
frisätts ut i blodet. Dessa substanser kan användas som biologiska markörer 
(biomarkörer) för hjärtsjukdom och fungerar som ett komplement till mera 
traditionella  undersökningsmetoder. Troponiner är proteiner som reglerar 
muskelcellernas kontraktionsförmåga. Cardiac troponin-I (cTnI), som endast 
finns i hjärtmuskulatur, läcker i samband med skador på hjärtmuskelceller ut 
i blodet. En ny, känslig analysmetod, med kapacitet att upptäcka mycket små 
cTnI nivåer i blodet användes för att undersöka hjärtmuskelskada hos 
hundar med olika grad av kronisk hjärtklaffsdegeneration. Resultaten visade 
att cTnI ökade med ökad sjukdomsgrad och en ökning förelåg redan hos 
hundar med lindrig sjukdom. Sambandet mellan inflammationsmarkören C-
reaktivt protein (CRP) och kronisk klaffdegenerationsgrad undersöktes 
också, och resultaten tyder på att CRP inte är kopplad till grad av kronisk 
hjärtklaffsdegeneration hos hund. Vid kronisk hjärtklaffsdegeneration uppstår 
förändringar i hjärtats stödjevävnad, vilket kan påverka hjärtats funktion. 
Matrix metalloproteinaser (MMP) är enzymer som anses spela en viktig roll 
för att reglera hjärtats stödjevävnad hos hundar  med kronisk 
hjärtklaffsdegeneration. Resultat från avhandlingen tyder på att det finns ett 
samband mellan MMP nivå i blodet och hjärtats sammandragningsförmåga 
hos hundar med kronisk hjärtklaffsdegeneration. 
Modern tredimensionell (3D) ultraljudsteknik kan förbättra 
utvärderingen av vänster kammares volym och form. För första gång har 
modern ”real-time” tredimensionell (RT3D) ultraljudsteknik använts för att 
utvärdera kammarens geometri hos hundar med olika långt framskriden 
kronisk hjärtklaffsdegeneration. Redan på ett tidigt stadium av 
sjukdomsutvecklingen kunde en liten ökning av vänster kammares volym 
ses, men först vid långt gången sjukdom kunde en påtaglig volymsökning 
påvisas. Vänster kammare uppvisade dessutom en mera rundad form hos 
hundar med långt gången sjukdom. 
I avhandlingen presenteras nya resultat  som ökar  kunskapen  om de 
komplexa förändringar som sker i  hjärtat hos hundar med kronisk 
hjärtklaffsdegeneration; kunskap som förhoppningsvis kommer att bidra till 
förbättrat omhändertagande av hjärtsjuka hundar i framtiden.  
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